Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

E. Merck claims Na+/H+-exchange inhibitors

April 5, 1996

New antiarrhythmics from Nisshin Flour Milling

April 5, 1996

Another antioxidant from Oxis: TX-153

April 5, 1996

BXT-51072 in line for clinical evaluation at Oxis

April 5, 1996

Novel vasoprotectants in AtheroGenics' pipeline

April 5, 1996

PB-005 slated to enter phase II

April 5, 1996

Baxter to distribute coronary bypass graft

April 5, 1996

Cypros synthesizes adenosine deaminase inhibitors

April 5, 1996

New potassium channel openers from Nippon Kayaku

April 5, 1996

Genentech claims vitronectin antagonists

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 31, 2025
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal
BioWorld Science
As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive...
Corcept looks to NDA following strong phase III ovarian cancer data
BioWorld
Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The...
Marks’ departure intensifies regulatory uncertainty at US FDA
BioWorld
Peter Marks’ March 28 letter giving one week’s notice of his resignation as director of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) is...